Publications

Found 1 results
Filters: Author is C.-P. Lee  [Clear All Filters]
2012
H. - H. Hsiao, Liu, Y. - C., Lee, C. - P., Chang, C. - S., and Lin, S. - F., Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia, vol. 11, pp. 317-321, 2012.
Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, et al. (2002). Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16: 1390-1393. http://dx.doi.org/10.1038/sj.leu.2402634 PMid:12094265 Bumm T, Muller C, Al-Ali HK, Krohn K, et al. (2003). Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101: 1941-1949. http://dx.doi.org/10.1182/blood-2002-07-2053 PMid:12411298 Deininger MW, Cortes J, Paquette R, Park B, et al. (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110: 1509-1519. http://dx.doi.org/10.1002/cncr.22936 PMid:17702093 Fabarius A, Giehl M, Frank O, Duesberg P, et al. (2005). Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19: 1573-1578. http://dx.doi.org/10.1038/sj.leu.2403861 PMid:15990860 Kharbanda S, Pandey P, Jin S, Inoue S, et al. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386: 732-735. http://dx.doi.org/10.1038/386732a0 PMid:9109492 Kim M, Lee S, Jung CK, Lim J, et al. (2008). Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. Int. J. Lab. Hematol. 30: 508-512. PMid:18983302 Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, et al. (2006). Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108: 2811-2813. http://dx.doi.org/10.1182/blood-2006-04-017400 PMid:16809614 Lin Y, Bruyere H, Horsman DE, Pantzar T, et al. (2006). Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet. Cytogenet. 170: 16-23. http://dx.doi.org/10.1016/j.cancergencyto.2006.04.012 PMid:16965950 Loriaux M and Deininger M (2004). Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk. Lymphoma 45: 2197-2203. http://dx.doi.org/10.1080/10428190410001723278 O’Brien SG, Guilhot F, Larson RA, Gathmann I, et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004. http://dx.doi.org/10.1056/NEJMoa022457 PMid:12637609 Tanaka H, Tanaka K, Oguma N, Ito K, et al. (2004). Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients. Cancer Genet. Cytogenet. 153: 133-143. http://dx.doi.org/10.1016/j.cancergencyto.2004.01.019 PMid:15350303 Terre C, Eclache V, Rousselot P, Imbert M, et al. (2004). Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18: 1340-1346. http://dx.doi.org/10.1038/sj.leu.2403399 PMid:15190256